接受DFCI联盟方案治疗的儿童、青少年及年轻成人急性淋巴细胞白血病患者的治疗完成率、门冬酰胺酶完成率及肿瘤学结局
该队列研究纳入332例青少年及年轻成人(AYA,15-49岁)和1159例儿童(1-14岁)Ph阴性急性淋巴细胞白血病患者,均接受DFCI联盟方案治疗。AYA患者治疗完成率低于儿童(60.8% vs 89.7%,p<0.001),主要因早期治疗失败率更高(14.5% vs 2.4%,p<0.001)。持续治疗1年者中,AYA患者门冬酰胺酶完成率(接受26周及以上)低于儿童(79.1% vs 89.6%,p<0.001),且巩固期门冬酰胺酶周数越多,总生存和无事件生存越高。
要点
- AYA患者治疗完成率低于儿童(60.8% vs 89.7%,p<0.001),主要因早期治疗失败率更高(14.5% vs 2.4%,p<0.001)。
- 因毒性、社会/个人或未知原因退出治疗不常见,但AYA患者高于儿童(9.3% vs 4.7%,p=0.001)。
- 持续治疗1年者中,AYA患者门冬酰胺酶完成率低于儿童(79.1% vs 89.6%,p<0.001),且巩固期门冬酰胺酶周数越多生存越高。
核心结论
- AYA患者治疗完成率和门冬酰胺酶完成率均低于儿童,主要因早期治疗失败率更高;巩固期门冬酰胺酶周数越多,总生存和无事件生存越高。
- 应致力于识别有早期治疗失败风险的患者并优化门冬酰胺酶给药。
研究设计与样本
- 队列研究,纳入332例AYA患者(15-49岁)和1159例儿童(1-14岁)Ph阴性急性淋巴细胞白血病患者,均接受DFCI联盟方案治疗。
主要发现
- AYA患者治疗完成率低于儿童(60.8% vs 89.7%,p<0.001)。
- AYA患者早期治疗失败率高于儿童(14.5% vs 2.4%,p<0.001)。
- 因毒性、社会/个人或未知原因退出治疗不常见,但AYA患者高于儿童(9.3% vs 4.7%,p=0.001)。
- 持续治疗1年者中,AYA患者5年总生存率为88.9%,儿童为96.4%(p<0.001)。
- 持续治疗1年者中,AYA患者门冬酰胺酶完成率(接受26周及以上)低于儿童(79.1% vs 89.6%,p<0.001);接受巩固期门冬酰胺酶周数越多的患者总生存和无事件生存越高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face worse outcomes than children. While pediatric-inspired protocols have improved outcomes, the ability of patients to complete these intensive regimens and the reasons for discontinuation are unknown. We analyzed a cohort of 332 AYA patients (aged 15-49 years) and 1159 children (aged 1-14 years) with Ph-negative ALL treated on DFCI consortium protocols. We found that AYA patients completed treatment at lower rates than children (60.8% vs. 89.7%, p < 0.001), primarily due to higher rates of early treatment failure (14.5% vs. 2.4%, p < 0.001). Withdrawal from treatment for toxicity, social/personal, or unknown reasons was uncommon, but higher among AYA patients (9.3% vs 4.7%, p = 0.001). Patients who remained on assigned therapy for one year had favorable overall survival (AYA 5-year OS 88.9%; children 5-year OS 96.4%; p < 0.001). Among patients who continued treatment for 1 year, AYA patients completed asparaginase (defined as receiving 26+ weeks) at lower rates than children (79.1% vs. 89.6%, p < 0.001). Patients who received more weeks of consolidation asparaginase had higher overall and event-free survival. Efforts should focus on identifying patients at risk for early treatment failure and optimizing asparaginase delivery.
引用
- Valtis YK, Flamand Y, Shimony S, et al. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024. PMID: 38177437. doi:10.1038/s41375-023-02115-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。